STILLCANNA INC. (CSE:STIL) (“StillCanna” or the “Company”) is pleased to announce that the Company has entered into a binding letter of intent with BioScience Enterprises, Inc. of California (“BioScience”) to supply C$6,000,000 of CBD isolate per month for an initial term of 6 months, such term may be extended by mutual agreement of the parties.

The Company anticipates that, subject to applicable stock exchange and regulatory approval, it will enter into a definitive agreement (the “Definitive Agreement”) with BioScience within the 60-day due diligence period under the binding letter of intent.


The Company expects to begin delivering on its contract in August of 2019 utilizing its Polish harvest of 1,500 hectares of hemp.

“We have visited BioScience Enterprises facilities,” stated Jason Dussault CEO of StillCanna. “We are impressed with their industry knowledge and capabilities. We are pleased to be a supplier of CBD isolate and hope to establish a long-standing relationship with BioScience. We believe this strategic arrangement compliments our business model and will help us reach our corporate milestones.”

Richard Parker, President of Operations, BioScience Enterprises, Inc. mentioned: “We are thrilled to be working with an innovative group like StillCanna on a partnership. Having a high standard for quality product is what makes BioScience a reputable supplier, without producers like StillCanna that wouldn’t be possible.”

ABOUT BIOSCIENCE ENTERPRISES, INC.

Since its inception in 2018 – Bioscience has emerged as a leading contract manufacturer and supplier of CBD nationwide. The company native to California has contracts across the continental USA and Canada for the supply of EU and domestic high-grade isolate, distillate and a variant of finished products. The company is housed in a secure 18,000 square foot plant, which is capable of a monthly output of 1.5 million glass tinctures, 2 million vape PET products, 1.5 million cartridges and 1.5 million disposable pens. BioScience supplies for many of America’s known brands and supplies bulk CBD to various industry manufacturing companies. The company intends to apply through the United States DEA for their own license to import hemp-derived CBD from around the world. BioScience strives to maintain its purest CBD supply on the market through a world-class quality assessment and quarantine process. BioScience currently estimates to contract over 100mm in gross sales through 2019.

For more information, please visit www.bioscience-enterprises.com

ABOUT STILLCANNA INC.

StillCanna Inc. (CSE: STIL) (www.StillCanna.com) is a Canadian early-stage life sciences company focused on large-scale CBD extraction in Europe. Based on a proprietary process and intellectual property, the Company is forecasted to be one of the lowest-cost CBD extractors operating in Europe. The Company has signed an extraction contract to be the exclusive extractor for Dragonfly BioSciences LLC, a United Kingdom-based supplier of CBD. Upon the completion of the Olimax Transaction, StillCanna is anticipated to be one of the largest processors and providers of market-ready CBD in Europe.

For more information, please visit www.StillCanna.com

On Behalf of the Board,
Joel Leonard,
Chief Financial Officer and Director
E-mail: accounting@jclpartners.ca

The CSE has not in any way passed upon the merits of and has neither approved nor disapproved the contents of this news release.

Cautionary Note Regarding Forward Looking Statements: This release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws, including statements regarding the expectation of the Company entering into the Definitive Agreement by the expiry of the due diligence period and the terms of the Definitive Agreement are expected to reflect the binding letter of intent as anticipated by management. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including that the Company will be able to enter into the Definitive Agreement by the expiry of the due diligence period and that the Definitive Agreement will reflect the terms of the binding letter of intent as anticipated by management. Although the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Such risk factors may include, among others, that the Company will not be able to enter into the Definitive Agreement by the expiry of the due diligence period, that the LOI will be terminated and that the anticipated CBD purchase will not be completed and that the Company may not supply CBD isolate to BioScience on the terms as anticipated by management. Readers are cautioned not to place undue reliance on forward-looking statements. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Source: www.newsfilecorp.com

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Executive Chairman, is scheduled to speak on a panel at the Cowen 2020 Boston Cannabis Conference on Wednesday, December 2, 2020 at 9:20 a.m. EST.

For more information regarding the Cowen 2020 Boston Cannabis Conference please visit: https://www.cowen.com/conferences-and-events/3rd-annual-boston-cannabis-conference/

Keep reading... Show less

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE:ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws

Keep reading... Show less

TerrAscend Corp. (“TerrAscend” or the “Company”) (CSE: TER) (OTCQX: TRSSF), a leading North American cannabis operator, today announced Jason Ackerman Chief Executive Officer and Executive Chairman of TerrAscend, Keith Stauffer Chief Financial Officer, and Jason Wild Chairman, will participate in three upcoming conferences:

  • Cowen’s 3rd Annual Boston Cannabis Conference, a virtual event taking place November 30-December 2 , 2020. Jason Ackerman will participate in a panel, U.S. MSOs: The West, on November 30, 2020 at 10:25 a.m. ET . Management will also host one-on-one meetings with investors throughout the conference.
  • 2020 Cantor Fitzgerald Virtual Cannabis MSO Summit, a virtual event taking place on December 15-16, 2020 . Jason Ackerman is scheduled to participate in a fireside chat on December 16 th at 1:00 p.m. ET . To register for the fireside chat: Click Here
  • 23 rd Annual Needham Virtual Growth Conference, a virtual event taking place January 11-15, 2021 . Jason Ackerman is scheduled to participate in a fireside chat on January 14, 2021 at 2:45 p.m. ET . Management will also host one-on-one meetings with investors throughout the conference. To register for the fireside chat: Click Here

The Canadian Securities Exchange (“CSE”) has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Keep reading... Show less
  • Aurora strategically positioned within two of the largest legal cannabis markets outside of Canada
  • Agreement with Israeli leader Cantek provides access to Israel’s drugstore channel
  • Finished product is co-branded under Aurora and Cantek brands

NYSE | TSX: ACB

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today it has entered into a strategic Supply Agreement (the “Agreement”) with Cantek Holdings (“Cantek”), one of Israel’s leaders in the medical cannabis field.

Keep reading... Show less